Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 1, 2014, Pages 93-102

  Yuasa, Yumiko ^a,b   Osaki, Tsukasa ^a   Makino, Hisashi ^a   Iwamoto, Noriyuki ^a   Kishimoto, Ichiro ^a   Usami, Makoto ^b   Minamino, Naoto ^a   Harada Shiba, Mariko ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b KOBE UNIVERSITY   (Japan)

Author keywords

Apolipoprotein C III; Low density lipoprotein apheresis; Proteomic analysis; Vitronectin

Indexed keywords

ALBUMIN; ANTITHROMBIN III; APOLIPOPROTEIN C3; CALCIUM; CHLORIDE; CHOLESTEROL; CLUSTERIN; D DIMER; EZETIMIBE; FIBRINOGEN; FIBRONECTIN; GELSOLIN; HAPTOGLOBIN; HEMOGLOBIN; HEPARIN COFACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN MU CHAIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIGMENT EPITHELIUM DERIVED FACTOR; POTASSIUM; PREALBUMIN; PROTEIN; SODIUM; TETRANECTIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VITAMIN D BINDING PROTEIN; VITRONECTIN;

ADSORPTION; ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; APHERESIS; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; CALCIUM BLOOD LEVEL; CASE REPORT; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; ELUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISOELECTRIC FOCUSING; LEUKOCYTE COUNT; LIPOPROTEIN APHERESIS SYSTEM; LIQUID; LOW DENSITY LIPOPROTEIN APHERESIS; MALE; MASS SPECTROMETRY; PLASMA VOLUME; POLYACRYLAMIDE GEL ELECTROPHORESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; TWO DIMENSIONAL ELECTROPHORESIS; WASTE FLUID;

APOLIPOPROTEIN C-III; LOW-DENSITY LIPOPROTEIN APHERESIS; PROTEOMIC ANALYSIS; VITRONECTIN;

APOLIPOPROTEIN C-III; ATHEROSCLEROSIS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; PROTEINS; PROTEOMICS; VITRONECTIN;

EID: 84893459364     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12056     Document Type: Article

References (26)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet A, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease 8th edn. New York: McGraw-Hil, 2001; 2863-2913.
2. Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial 2003;7:397-401.
3. de Gennes JL, Touraine R, Maunand B, Truffert J, Laudat P. [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment]. Bull Mem Soc Med Hop Paris 1967;118:1377-1402.
4. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975;1:1208-1211.
5. Mineshima M, Agishi T, Hasuo Y, Kaneko I, Era K, Ota K. Effect of membrane trapping in plasma fractionator on separative characteristics. Int J Artif Organs 1988;11:191-194.
6. Usami M, Horiuchi T, Emura M etal. Thermal effect of LDL/HDL separation in membrane filtration; thermofiltration. Trans Am Soc Artif Intern Organs 1985;31:716-721.
7. Nosé Y, Usami M, Malchesky PS etal. Clinical thermofiltration: initial application. Artif Organs 1985;9:425-427.
8. Tani N. Development of selective low-density lipoprotein (LDL) apheresis system: immobilized polyanion as LDL-specific adsorption for LDL apheresis system. 1996. Ther Apher 2000;4:135-141.
9. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5:613-622.
10. Kobayashi S, Oka M, Moriya H, Maesato K, Okamoto K, Ohtake T. LDL-apheresis reduces P-Selectin, CRP and fibrinogen-possible important implications for improving atherosclerosis. Ther Apher Dial 2006;10:219-223.
11. Mabuchi H, Koizumi J, Shimizu M etal. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998;82:1489-1495.
12. Nishimura S, Sekiguchi M, Kano T etal. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999;144:409-417.
13. Takata M, Kawashiri M, Yamagishi M, Mabuchi H. Study on prognosis of patients with familal hypercholesterolemia (FH) who have withdrawn from LDL apheresis. Lipid 2007;18:86-90.
14. Harada-Shiba M, Nakahama H, Nagumo S etal. Long-term prognosis of LDL-apheresis in homozygous and heterozygous familial hypercholesterolemia. Jpn J Apher 2006;25:65.
15. Kojima S, Harada-Shiba M, Toyota Y etal. Changes in coagulation factors by passage through a dextran sulfate cellulose column during low-density lipoprotein apheresis. Int J Artif Organs 1992;15:185-190.
16. Cucuianu M, Dican L. Coagulation factor XIII and atherothrombosis. A mini-review. Rom J Intern Med 2003;41:339-355.
17. Klingel R, Fassbender T, Fassbender C, Gohlen B. From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis. Ther Apher Dial 2003;7:350-358.
18. Edwards AV, White MY, Cordwell SJ. The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics 2008;7:1824-1837.
19. Dihazi H, Koziolek MJ, Sollner T etal. Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol Dial Transplant 2008;23:2925-2935.
20. Kojima S, Harada-Shiba M, Yamamoto A. Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther Apher 1997;1:309-313.
21. Knisel W, Di Nicuolo A, Pfohl M etal. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. J Intern Med 1993;234:479-487.
22. Mabuchi H, Michishita I, Takeda M etal. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987;68:19-25.
23. Ekmekci OB, Ekmekci H. Vitronectin in atherosclerotic disease. Clin Chim Acta 2006;368:77-83.
24. Peng L, Bhatia N, Parker AC, Zhu Y, Fay WP. Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries. Arterioscler Thromb Vasc Biol 2002;22:934-939.
25. Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond) 2008;114:611-624.
26. Pollin TI, Damcott CM, Shen H etal. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008;322:1702-1705.